INCOG BioPharma Services, a contract development and manufacturing organization (CDMO) specializing in sterile injectable biopharmaceuticals, has announced strategic expansion projects for 2025. These efforts include the physical expansion of its Fishers-based facilities, scaling up of core filling capabilities, adding significant new finishing capabilities, and strategic hiring focused on attracting top-tier talent.

Last September, the company broke ground on its second building, adjacent and connected to the current manufacturing facility, on its Fishers, IN campus. The 113,000-square-foot facility expansion will enable the company to provide device assembly capacity in support of autoinjectors, pens, wearable injectors, and syringe accessorizing. The addition will also support new labeling and final packaging capabilities.

Additionally, the high-speed Optima syringe and cartridge filling line that was delivered last November, is installed and is being prepared for qualification. The new filling line adds 100,000,000 units of syringe and cartridge capacity and will be GMP-ready this September.

“Our new high-speed Optima filling line represents a significant step forward for INCOG, allowing us to efficiently fill both syringes and cartridges for large-scale commercial projects,” said Cory Lewis, CEO and President of INCOG. “This investment, coupled with expanding the facility and commissioning automated device assembly and packaging lines, reinforces our commitment to providing end-to-end solutions that meet the evolving needs of our clients.”

The 2025 INCOG expansion also includes a strategic hiring initiative, which will bring total employment to more than 350 employees by the end of summer, including manufacturing, quality assurance, and client support services.